Cristina Cruz Zambrano
Member of the Cancer profiling research line
Email: cristina.cruz@umedicina.cat
ORCID: 0000-0002-6474-7504
Scientific Profile: URECERCA
Cristina Cruz is a lecturer at the University of Vic – Central University of Catalonia (UVic-UCC). Her research focuses on cancer biomarkers of prognosis and treatment response.
She graduated in Biochemistry in 1996 (University of Barcelona) and earned the doctorate in Biochemistry in 2001. In 2006 she graduated in Medicine (University of Barcelona) and is a Medical Oncology specialist since 2011. From 2011 to 2018 she was a clinical and translational investigator at Vall d’Hebron Institute of Oncology (VHIO). She participated in a number of clinical trials in the field of early drug development (Phase I) and Phase II & III clinical trials investigating targeted therapies for hereditary breast and ovarian cancers. As a postdoctoral researcher from VHIO’s Experimental Therapeutics Group, she also developed translational projects to investigate the determinants of treatment response and resistance among BRCA1/2 germline mutation carriers, including the functional biomarker RAD51. In 2019, she joined the Faculty of Medicine at UVic-UCC, where she teaches Human Genetics, Histology, Medical Embryology and Physiology.
My last happenings:
TR2Lab was present at the Spanish Society of Geriatric and Gerontological Nursing Congress
Recently, Dr. Marta Casals, member of TR2Lab, participated in the Congress of the Spanish Society of Geriatric and Gerontological Nursing (SEEGG), a leading scientific meeting for professionals dedicated to the care of older adults. As part of the scientific programme, Dr. Marta Casals presented an oral communication entitled “Translation, Cross-Cultural Adaptation and Validation of the Wound-QoL-17 Scale into Catalan.” The study aimed to provide a validated instrument for assessing the impact of chronic wounds on the quality of life of Catalan-speaking patients. The presentation described the translation and cultural adaptation process of the questionnaire, as well as the psychometric validation [...]
Molecular autopsy identifies the NaV1.5 p.Leu96Pro variant causing sodium current loss-of-function in unexplained sudden cardiac death
Authors: Albert Rigat Pujolasa, Rebecca Martínez-Moreno, David Carreras, Yajaira Alvarado-Cervantes, Elisabet Selga, Ramon Brugada, Guillermo J. Pérez, Fabiana S. Scornik Forensic Science International: Genetics, 86 (2027) 103587 DOI: 10.1016/j.fsigen.2026.103587 Read More Abstract Molecular autopsy can identify candidate variants in unexplained sudden cardiac death (SUD), but functional evidence is often required to support pathogenic interpretation and family risk assessment. Here, we investigated the functional consequences of the SCN5A c.287 T >C (NaV1.5_p.Leu96Pro) variant, identified in a 29-year-old man who died of SUD. Cascade screening identified additional relatives carrying the variant, with variable clinical expression. Sodium current (INa) was [...]
TR2Lab Joins Global Experts at the ERS International Congress 2026
Dr. Renata Da Palma, member of TR2Lab, participated in the ERS International Congress 2026 held in Barcelona, one of the world's largest and most influential meetings in respiratory medicine and science. During the event, she presented TR2Lab’s research on the anti-inflammatory effects of photobiomodulation therapy in an experimental model of asthma-COPD overlap. The congress brought together researchers, clinicians, and healthcare professionals from across the globe to share the latest advances in respiratory health, fostering scientific exchange and international collaboration. Scientific meetings such as ERS play an essential role in advancing research by facilitating knowledge sharing, promoting innovation, and creating new [...]
